Literature DB >> 6725035

Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy.

P J Fitzpatrick, G A Thompson, W M Easterbrook, B L Gallie, D G Payne.   

Abstract

We report 1,166 tumors of the eyelids that were treated by single or fractionated exposures to doses of 20-60 Gy. The five year tumor control rate was 95% for basal cell and 93.3% for squamous cell carcinoma. Irradiation was equally successful in primary cases and in those recurrent following surgery. Recurrence following irradiation was managed by surgery or further irradiation. The cosmetic and functional results were generally excellent and readily accepted by most patients. The overall complication rate was 9.6% with fewer than one-half rated as serious; these problems mainly occurred with large tumors that had destroyed normal tissues. In only 14 (1.2%) patients was death related to the tumor. Approximately one-half of the patients received a dose of 35 Gy in five daily fractions, one-quarter, 20 to 22.5 Gy in a single exposure and the others with larger tumors 42.5-60 Gy in 10 to 30 exposures in two to six weeks. Radiotherapy is a safe and cost effective treatment for eyelid tumors.

Entities:  

Mesh:

Year:  1984        PMID: 6725035     DOI: 10.1016/0360-3016(84)90023-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Electron therapy for orbital and periorbital lesions using customized lead eye shields.

Authors:  Keiji Hayashi; Kunito Hatsuno; Ryo-ichi Yoshimura; Toshiaki Iida; Fumio Ayukawa; Kazuma Toda; Hisashi Taniguchi; Hitoshi Shibuya
Journal:  Ophthalmologica       Date:  2008-11-26       Impact factor: 3.250

2.  Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids.

Authors:  Mark S Nestor; Brian Berman; David Goldberg; Armand B Cognetta; Michael Gold; William Roth; Clay J Cockerell; Brad Glick
Journal:  J Clin Aesthet Dermatol       Date:  2019-02-01

3.  The treatment of periocular basal cell carcinomas by radiotherapy.

Authors:  J M Rodriguez; G P Deutsch
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

4.  Cis-platinum chemotherapy for ocular basal cell carcinoma.

Authors:  M Morley; P T Finger; M Perlin; L R Weiselberg; D S DeBlasio
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

5.  Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.

Authors:  M Hata; I Koike; J Maegawa; A Kaneko; K Odagiri; T Kasuya; Y Minagawa; H Kaizu; Y Mukai; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-10-28       Impact factor: 3.621

Review 6.  Oculoplastic aspects of ocular oncology.

Authors:  C Rene
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

7.  Reirradiation for Recurrent Scalp Angiosarcoma: Dosimetric Advantage of PBT over VMAT and EBT.

Authors:  Tal Eitan; Nicholas J Damico; Rajesh Pidikiti; Michael Z Kharouta; Donald Dobbins; Frederick B Jesseph; Mark Smith; Ankit Mangla; Theodoros N Teknos; David B Mansur; Mitchell Machtay; Min Yao; Aashish D Bhatt
Journal:  Int J Part Ther       Date:  2019-12-16

8.  Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study.

Authors:  M F Avril; A Auperin; A Margulis; A Gerbaulet; P Duvillard; E Benhamou; J C Guillaume; R Chalon; J Y Petit; H Sancho-Garnier; M Prade; J Bouzy; D Chassagne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Role of in vivo dosimetry with radiochromic films for dose verification during cutaneous radiation therapy.

Authors:  Hong-Wei Liu; James Gräfe; Rao Khan; Ivo Olivotto; J Eduardo Villarreal Barajas
Journal:  Radiat Oncol       Date:  2015-01-10       Impact factor: 3.481

10.  Results of radical radiotherapy for squamous cell carcinoma of the eyelid.

Authors:  Koji Inaba; Yoshinori Ito; Shigenobu Suzuki; Shuhei Sekii; Kana Takahashi; Yuuki Kuroda; Naoya Murakami; Madoka Morota; Hiroshi Mayahara; Minako Sumi; Takashi Uno; Jun Itami
Journal:  J Radiat Res       Date:  2013-06-07       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.